A Washington federal judge has rejected a lawsuit from Seattle-based biotechnology firm HDT Bio against an Indian pharmaceutical company. HDT Bio had claimed that the Indian firm had appropriated its mRNA platform for the development of a new COVID-19 vaccine, and the dispute amount was close to one billion dollars. The information made public on Monday indicates this litigation, at least for now, has been dismissed.
As of now, it’s not clear what effect this decision will have on the operations of HDT Bio, or how it may impact the broader landscape of intellectual property rights within the biotechnology and pharmaceutical sectors. Neither is it clear whether HDT Bio plans to appeal the judge’s decision or pursue other legal avenues.
For more detailed information on this case, readers can access the original report of the lawsuit’s dismissal.